secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-06-21T23:59:59+00:00
Accession:  0001193125-24-165903
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics enters ATM equity offering agreement for up to $350M
--------------------------------------------------------------

- Filed prospectus supplement registering up to $350M in common stock sales.
- Agents Leerink Partners and Cantor Fitzgerald will receive 3.0% commission per share sold.
- No minimum sales required; sales made via 'at-the-market' methods under Rule 415.
- Agreement dated June 21, 2024; no escrow or trust arrangement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000119312524165903/0001193125-24-165903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000119312524165903/d781699d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-165903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer